Trials / Completed
CompletedNCT04372355
Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Srinakharinwirot University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who will receive standard wound treatment in combination with adjuvant therapy WF10 to compare the change of HbA1c levels at baseline and after treatment.
Detailed description
Single-center, Prospective Open-labelled One Group Pretest Posttest Pilot Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WF10 | WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks. |
Timeline
- Start date
- 2019-06-19
- Primary completion
- 2020-04-30
- Completion
- 2020-06-19
- First posted
- 2020-05-04
- Last updated
- 2020-10-22
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04372355. Inclusion in this directory is not an endorsement.